Buprenorphine does not aggrevate ischemic neuronal injury in experimental focal cerebral ischemia
dc.contributor.author | Cam, Ertuğrul | |
dc.contributor.author | Yıldız, Ayşegül | |
dc.contributor.author | Kılıç, Ertuğrul | |
dc.contributor.buuauthor | Yuluǧ, Burak | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-9704-6173 | tr_TR |
dc.contributor.researcherid | O-8322-2016 | tr_TR |
dc.contributor.scopusid | 6507583384 | tr_TR |
dc.date.accessioned | 2024-03-13T05:53:53Z | |
dc.date.available | 2024-03-13T05:53:53Z | |
dc.date.issued | 2007-09 | |
dc.description.abstract | Buprenorphine has been increasingly used as maintenance therapy in opioid dependence as an alternative to methadone and other pharmacological therapies. However, available data suggest increased risk of cerebrovascular events in opioid-dependent patients. Therefore, an opioid that provides safety with regard to neurological function should be considered by opioid-dependent patients. The evidence for the in vitro neurotoxic effects of buprenorphine is rapidly increasing. In order to clarify whether buprenorphine is also neurotoxic under the condition of cerebral ischemia in vivo, we applied an acute dose of buprenorphine in a transient model of focal cerebral ischemia in rats. Our study provides preclinical evidence for the usage of buprenorphine during the postoperative period following ischemic events as well as for the maintenance therapy of opioid-dependent patients wherein the risk of cerebrovascular events is increased. | en_US |
dc.identifier.citation | Yuluǧ, B. vd. (2007). "Buprenorphine does not aggrevate ischemic neuronal injury in experimental focal cerebral ischemia". Journal of Neuropsychiatry and Clinical Neurosciences, 19(3), 331-334. | en_US |
dc.identifier.doi | https://doi.org/10.1176/appi.neuropsych.19.3.331 | en_US |
dc.identifier.endpage | 334 | tr_TR |
dc.identifier.issn | 0895-0172 | |
dc.identifier.issue | 3 | tr_TR |
dc.identifier.pubmed | 17827420 | tr_TR |
dc.identifier.scopus | 2-s2.0-85047698574 | tr_TR |
dc.identifier.startpage | 331 | tr_TR |
dc.identifier.uri | https://neuro.psychiatryonline.org/doi/epdf/10.1176/jnp.2007.19.3.331 | en_US |
dc.identifier.uri | https://hdl.handle.net/11452/40361 | en_US |
dc.identifier.volume | 19 | tr_TR |
dc.identifier.wos | 000249137700012 | |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Amer Psychiatric Publishing, Inc | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.journal | Journal of Neuropsychiatry and Clinical Neurosciences | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Traumatic injury | en_US |
dc.subject | Psychiatry | en_US |
dc.subject | Spinal-cord | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Stroke | en_US |
dc.subject | Heroin | en_US |
dc.subject | Naloxone | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Apoptosis | en_US |
dc.subject | Cells | en_US |
dc.subject | Trial | en_US |
dc.subject.emtree | Buprenorphine | en_US |
dc.subject.emtree | Methadone | en_US |
dc.subject.emtree | Buprenorphine | en_US |
dc.subject.emtree | Narcotic antagonist | en_US |
dc.subject.emtree | Acute drug administration | en_US |
dc.subject.emtree | Animal experiment | en_US |
dc.subject.emtree | Animal model | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Brain ischemia | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Drug indication | en_US |
dc.subject.emtree | Maintenance therapy | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Nerve cell lesion | en_US |
dc.subject.emtree | Neurotoxicity | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Opiate addiction | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Rat | en_US |
dc.subject.emtree | Animal | en_US |
dc.subject.emtree | Brain infarction | en_US |
dc.subject.emtree | Brain ischemia | en_US |
dc.subject.emtree | Disease model | en_US |
dc.subject.emtree | Drug screening | en_US |
dc.subject.emtree | Laser Doppler flowmetry | en_US |
dc.subject.emtree | Methodology | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Wistar rat | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Brain ischemia | en_US |
dc.subject.mesh | Buprenorphine | en_US |
dc.subject.mesh | Cerebral infarction | en_US |
dc.subject.mesh | Disease models, animal | en_US |
dc.subject.mesh | Drug evaluation, preclinical | en_US |
dc.subject.mesh | Laser-doppler flowmetry | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Narcotic antagonists | en_US |
dc.subject.mesh | Rats | en_US |
dc.subject.mesh | Rats, wistar | en_US |
dc.subject.scopus | Nabumetone; 6-Methoxy-2-Naphthylacetic Acid; Localized Surface Plasmon Resonance | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.subject.wos | Psychiatry | en_US |
dc.subject.wos | Neurosciences | en_US |
dc.title | Buprenorphine does not aggrevate ischemic neuronal injury in experimental focal cerebral ischemia | en_US |
dc.type | Article | en_US |
dc.wos.quartile | Q2 (Clinical neurology) | en_US |
dc.wos.quartile | Q3 | en_US |